Protia Inc. (KOSDAQ:303360)

Market Cap	64.32B
Revenue (ttm)	12.43B
Net Income (ttm)	2.86B
Shares Out	12.88M
EPS (ttm)	222.13
PE Ratio	22.49
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,650
Average Volume	193,462
Open	5,790.00
Previous Close	5,720.00
Day's Range	5,380.00 - 5,790.00
52-Week Range	2,430.00 - 6,300.00
Beta	0.09
RSI	50.44
Earnings Date	n/a

About Protia

Protia Inc. designs, develops, and sells diagnostic kits in South Korea. The company offers PROTIA Allergy-Q, an assay kit for quantitative determination of specific IgE antibodies against individual allergens in human serum using immunoblotting technique; ImmuneCheck IgG, a whole blood test kit for total IgG concentration measurement; and TriCheck-C, an in vitro diagnostic kit for the qualitative test of human chorionic gonadotropin in human urine samples for the pregnancy diagnosis. It also provides protia food iga, a chronic food intolerance...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 303360

Financial Performance

In 2024, Protia's revenue was 10.51 billion, an increase of 27.79% compared to the previous year's 8.23 billion. Earnings were 2.44 billion, an increase of 427.52%.